Fortrea Holdings Inc. Q4 FY2025 earnings call

Anshul highlighted commercial excellence with securing significant new and repeat wins in Q4, using the three R's (reach, expanding top of funnel; relevance, creating bespoke solutions; repeat, earning next study) to guide growth. Operational excellence focused on optimizing project management, embedding risk-based quality management, streamlining processes enabled by technology, and investing in AI, machine learning for clinical research. Also mentioned improving employee engagement as seen in annual survey with increased scores.

Fourth quarter revenue was $660.5 million, 5.2% lower than the prior year quarter. The decline was driven by lower pass-through costs in clinical pharmacology and clinical development businesses, and FSP headwinds. Full-year 2025 revenue was $2,723.4 million, in line with guidance range, up 1% year-on-year, driven by higher revenue in clinical pharmacology business partially offset by lower FSP revenue. Adjusted EBITDA for the quarter was $54 million, and for the full year was $189.9 million towards the upper end of guidance range. Positive operating and free cash flow in Q4 and full year, with $153 million in gross savings and $93 million in net savings for the year.

2026 guidance: targeting revenue in the range of $2.55 billion to $2.65 billion and adjusted EBITDA in the range of $190 million to $220 million. Continue cost savings programs in 2026 targeting incremental cost reductions of approximately $70 to $80 million in gross savings and $40 to $50 million in net savings as moving closer to normalized compensation levels by end of 2026.

Concerns about AI impact on CRO sector, but Fortria views AI as a force multiplier that accelerates execution and expands demand for CROs, with AI automating specific task-level work rather than replacing core roles, and quality remaining non-negotiable.

Q: Patrick Donnelly asked about outlook, bookings mix, margins.

A: Anshul said cautiously optimistic, Jill talked about margin levers.

Q: Elizabeth Anderson asked about bookings mix, accounts payable.

A: Anshul said mix in line, Jill talked about AP factors.

Q: Eric Caldwell asked about RFP flow, bookings mix, win rate.

A: Anshul talked about mix, win rates, RFP flow.

Q: David Winley asked about customer mix, clinical pharmacology trends.

A: Anshul disaggregated clinical pharmacology details.

Q: Jalendra Singh asked about AI impact, customer conversations.

A: Anshul talked about AI as force multiplier, no major change in outsourcing behavior.

Q: Max Smock asked about direct fee revenue mix impact on margins.

A: Jill talked about revenue mix evolution.

Q: Anne Hines asked about margin goals, cancellations.

A: Anshul talked about margin goal mid-teens, stable cancellations.

Q: Justin Bowers asked about AI impact on discovery, clinical trial ops functions.

A: Anshul talked about AI impact on discovery, task automation in various areas